Massive hope for pancreatic cancer pill after trial saw tumours vanish
Experts are calling it the biggest breakthrough in pancreatic cancer treatment for decades — a daily pill that appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest and hardest-to-treat cancers.
Pancreatic cancer experts are hailing a daily pill combination of daraxonrasib and chemotherapy as a potential breakthrough in treating the notoriously hard-to-treat and deadly disease. In early clinical trials, one in 12 patients given the pill with chemotherapy saw their cancer become completely undetectable on scans while tumours stopped growing in nearly all 61 participants with advanced, metastatic pancreatic cancer.
However, doctors stress that while the results are "incredibly exciting", it is still early days and more research is needed to determine how long the disease might be controlled and whether it could lead to a cure. Cancer Research UK described the development as "the biggest leap forward in decades" for pancreatic cancer patients, praising the drug for "drugging the undruggable."
Pancreatic cancer has the lowest survival rate of all common cancers in the UK, with most patients surviving only months, not years, despite chemotherapy shrinking tumours temporarily. The trial followed patients for an average of a year and a half, with some surviving much longer without recurrence. Longer studies are needed to establish if the cancer can be put into remission and for how long.
If successful, the treatment could offer patients more time that extends beyond the current months of survival for advanced disease.
Rewritten by urgent.news; may contain errors — check the original.
This story
This is one outlet's version. Read the fullest account.